HomeAI · summaries
Storia in 2 fonti
GSK wagers up to $1.3B on a different kind of cancer drug
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
GSK wagers up to $1.3B on a different kind of cancer drug
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
- ·
endpoints.news
GSK to license Hutchmed’s dual-action cancer drug for $110M upfront
GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.